Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business UpdatesAccesswire • 02/13/26
Biotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader24/7 Wall Street • 02/12/26
The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine divisionWSJ • 02/12/26
FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'New York Post • 02/11/26
MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLAZacks Investment Research • 02/11/26
Moderna Stock Alert: - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Moderna Investors - MRNANewsfile Corp • 02/11/26
Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst saysMarket Watch • 02/11/26
The FDA has refused to review Moderna's application to sell a new flu shot, the latest move by the Trump administration against vaccinesWSJ • 02/11/26
Moderna Plunges After FDA Rejects Its Messenger-RNA-Based Flu ShotInvestors Business Daily • 02/10/26
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010Accesswire • 02/10/26
The FDA has refused to review Moderna's application to sell a new flu shot, the latest move by the administration against vaccinesWSJ • 02/10/26